These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11741159)

  • 1. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen.
    Le Moing V; Chêne G; Carrieri MP; Alioum A; Brun-Vézinet F; Piroth L; Cassuto JP; Moatti JP; Raffi F; Leport C;
    AIDS; 2002 Jan; 16(1):21-9. PubMed ID: 11741159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
    Masquelier B; Pereira E; Peytavin G; Descamps D; Reynes J; Verdon R; Fleury H; Garraffo R; Chêne G; Raffi F; Brun-Vézinet F;
    J Clin Virol; 2005 May; 33(1):75-8. PubMed ID: 15797369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.
    Friedl AC; Ledergerber B; Flepp M; Hirschel B; Telenti A; Furrer H; Bucher HC; Bernasconi E; Weber R;
    AIDS; 2001 Sep; 15(14):1793-800. PubMed ID: 11579241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).
    Vray M; Meynard JL; Dalban C; Morand-Joubert L; Clavel F; Brun-Vézinet F; Peytavin G; Costagliola D; Girard PM;
    Antivir Ther; 2003 Oct; 8(5):427-34. PubMed ID: 14640390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological response to protease inhibitor therapy in an HIV clinic cohort.
    Staszewski S; Miller V; Sabin C; Carlebach A; Berger AM; Weidmann E; Helm EB; Hill A; Phillips A
    AIDS; 1999 Feb; 13(3):367-73. PubMed ID: 10199227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.
    Antinori A; Cozzi-Lepri A; Ammassari A; Trotta MP; Nauwelaers D; Hoetelmans R; Murri R; Melzi S; Narciso P; Nasta P; Zaccarelli M; Santopadre P; Vecchiet J; Izzo CM; Maonforte Ad;
    Antivir Ther; 2004 Apr; 9(2):291-6. PubMed ID: 15134192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
    Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
    AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
    Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
    J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
    Lucas GM; Chaisson RE; Moore RD
    AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.
    Clumeck N; Goebel F; Rozenbaum W; Gerstoft J; Staszewski S; Montaner J; Johnson M; Gazzard B; Stone C; Athisegaran R; Moore S;
    AIDS; 2001 Aug; 15(12):1517-26. PubMed ID: 11504984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
    Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
    AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
    Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
    AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.
    Deeks SG; Hecht FM; Swanson M; Elbeik T; Loftus R; Cohen PT; Grant RM
    AIDS; 1999 Apr; 13(6):F35-43. PubMed ID: 10397555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
    Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
    Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.
    Ioannidis JP; Havlir DV; Tebas P; Hirsch MS; Collier AC; Richman DD
    AIDS; 2000 Jul; 14(11):1481-8. PubMed ID: 10983634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.